POWERFUL NEWS:

MMRF PRESS RELEASES


Chief Operating Officer of the Multiple Myeloma Research Foundation (MMRF), Walter Capone, Named to the 2013 Pharmavoice 100


Capone Honored for Building Collaborative Partnerships to Drive Toward a Cure

Norwalk, CT — August 8, 2013

The Multiple Myeloma Research Foundation (MMRF) is proud to announce that Walter M. Capone, MMRF Chief Operating Officer, has been selected for the 2013 PharmaVOICE 100. This annual award recognizes top industry leaders for their positive contributions across sectors such as pharmaceutical, biotechnology, contract research, clinical trial, research and development, patient education, advocacy and more. Kathy Giusti, Founder and CEO of the MMRF, was named to the PharmaVOICE 100 in 2009.

As Chief Operating Officer of the MMRF, Capone is focused on accelerating a cure by bringing together researchers and clinicians with the pharmaceutical, biotech, and diagnostic industries, as well as government agencies and informatics technology partners. Capone took a lead role in developing C-MAP, an unprecedented early-access program with partner Onyx Pharmaceuticals, to make Kyprolis® (carfilzomib) available prior to FDA approval.

PharmaVOICE editors recognized Capone for his innovative leadership of the MMRF, “Collaboration and inventiveness define Walter Capone. These are the characteristics that have helped him in contributing to changing the treatment landscape for multiple myeloma patients.”

Capone has also helped to spearhead the development of the groundbreaking MMRF CoMMpassSM Study, a longitudinal study involving more than 50 academic and community centers in following 1,000 myeloma patients from the time of their diagnosis through their journey with the disease. To enable the CoMMpass Study, Capone led the development of a novel pre-competitive consortium of pharmaceutical, biotech, and technology companies that, along with all participating centers, agreed to give up intellectual property rights in order to create the richest clinical and molecular database of any cancer available publicly. The comprehensive clinical and molecular data from CoMMpass will be placed in an open-access data portal, which will launch later this year and be available to researchers and clinicians worldwide to drive discoveries and hypotheses to enable precision medicine.

“I am honored to be named to the PharmaVOICE 100 and to be recognized by my peers is such a humbling experience unto itself,” said Mr. Capone. “I have been incredibly fortunate to work closely with such extremely talented and passionate researchers, scientists and other partners who are accelerating the development of the next generation of myeloma treatments. These efforts would not have been possible without the support of patients who inspire our work, and the efforts of my talented colleagues at the MMRF backed by our CEO Kathy Giusti.”

The 2013 PharmaVOICE 100 Honorees were selected by PharmaVOICE editors based on thousands of nominations, and judged on their ability to motivate and influence research and development, technology, creativity and strategy – positively impacting the Life Sciences industry through their actions. Winners are published in the July/August issue of PharmaVOICE, which was released on August 1, 2013.

About Multiple Myeloma
Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 41 percent, one of the lowest of all cancers. In 2013, more than 20,000 adults in the United States will be diagnosed with multiple myeloma and nearly 11,000 people are predicted to die from the disease.

About the Multiple Myeloma Research Foundation (MMRF)
The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)(3) non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world's number-one private funder of multiple myeloma research, the MMRF has raised over $225 million since its inception and directs 90% of total budget to research and related programming. As a result, the MMRF has been awarded Charity Navigator’s coveted four-star rating for 10 consecutive years, the highest designation for outstanding fiscal responsibility and exceptional efficiency. For more information about the MMRF, please visit: www.themmrf.org.

Media contacts:
MMRF
Anne Quinn Young, MPH
203-536-8691
QuinnYoungA@themmrf.org